Monday, February 17, 2025

GET OUR FREE E-NEWSLETTER

“You may choose to look the other way, but you can never say again that you did not know.”

— William Wilberforce

Search

WHO Names 17 Pathogens as Top Priorities for Global Vaccine Development

WHO Names 17 Pathogens as Top Priorities for Global Vaccine Development

A new World Health Organization (WHO) study published in eBioMedicine last week highlights 17 viral and bacterial pathogens that are major sources of endemic disease around the world and that WHO officials believe should be urgently prioritized for vaccine development. The study marks the WHO’s first global effort to systematically prioritize endemic pathogens with epidemic […]

Moderna/Merck’s Combo Melanoma Cancer mRNA Therapeutic May Be Ready Next Year

Moderna/Merck’s Combo Melanoma Cancer mRNA Therapeutic May Be Ready Next Year

The CEO of Moderna, Inc., Stephane Bancel, said last week that his company may introduce a new mRNA (messenger ribonucleic acid) biologic to treat melanoma cancer as early as 2025. Moderna has been working in partnership with Merck, Inc. to develop a mRNA-based shot that targets skin cancer cells. The product, mRNA-4157 (V940), would be […]

U.S. Government Gives Moderna $176 Million to Develop mRNA Bird Flu Biologic

U.S. Government Gives Moderna 6 Million to Develop mRNA Bird Flu Biologic

On July 2, 2024, the U.S. government awarded a $176 million contract to Moderna, Inc. for the development of an mRNA H5N1 avian influenza biologic labeled a “vaccine,” as the media reports concerns about bird flu in dairy cows and farm workers in multiple states. The funds from the U.S. Biomedical Advanced Research and Development […]

BARDA Awards $9.27 Million Contract to Evaluate Oral Pill COVID Vaccine

BARDA Awards .27 Million Contract to Evaluate Oral Pill COVID Vaccine

Biotechnology firm Vaxart, Inc. announced on Jan. 19, 2024 that it received a $9.27 million contract from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to fund preparations for a Phase IIb clinical trial to evaluate the company’s oral pill XXB COVID-19 vaccine candidate. The trial is expected to involve 10,000 participants and will […]

Only Remaining HIV Vaccine Efficacy Trial Fails in Africa

Only Remaining HIV Vaccine Efficacy Trial Fails in Africa

The latest effort to develop an HIV (human immunodeficiency viruses) vaccine in Uganda, Tanzania and South Africa was halted on Dec. 6, 2023 after preliminary data showed that the vaccine would not be effective at preventing HIV infection. The PrEPVacc (pre-exposure prophylaxis vaccine) phase 2b trial was testing two different combinations of experimental HIV vaccines, […]

Search in Site

To search in site, type your keyword and hit enter

Search